Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Tekmira Pharmaceuticals Corp TKMR

Sector: Healthcare | Sub-Sector: Biotechnology

Tekmira Pharmaceuticals Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.
Price: $11.86 Volume: 429,277
Change: +$0.05 % Change: +0.42%
Day High/Low: 12.07/11.69 52 Week High/Low: 29.93/8.86
Last Traded: June 30, 2015 12:00 Transaction Volume: 2300
Open: 11.80 Previous Close: 11.81
Bid: 11.35 Ask: 13.47
Bid Size: 1000 Ask Size: 100
Market Cap: 643.1m Shares Out: 54.2m
PE Ratio: N/A Dividend Yield: N/A


The Calandra Report: BioCryst Pharma, nothing to sneeze at

Thom Calandra   October 15, 2014
0 stars

Canadian Biotech comes back to life: A buyer's guide

Everything you could ever want to know about biotech, biomed and bio investments up north.

Tony Pullen   January 21, 2014
0 stars

Latest Bullboard Posts

  • Fibos at 8 13 and 21

    0 stars

    Happy June folks. My last purchase at 13.79 GLTA Peace

    1.5 stars

  • RE:Low volume today

    5 stars

    4 stars

  • Low volume today

    0 stars

    This upward movement may take a bit of a breather- it's certainly been a nice move, hopefully just a little consolidation and then...

    2.5 stars

  • Sweet

    0 stars

    Yesterday's action confirms a decisive break of the slide we've endured over the last ten months, and it came on volume. What was...

    1.5 stars

  • Volume

    0 stars

    Hasn't really abated like it usually does. If we hang in there over the lunchtime lull, we can look forward to a strong close. Somewhere...

    1.5 stars